Zurcher Kantonalbank Zurich Cantonalbank Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 107.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,749 shares of the company's stock after purchasing an additional 168,975 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Moderna worth $13,586,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. OFI Invest Asset Management bought a new position in Moderna during the 4th quarter valued at approximately $48,000. Amundi raised its holdings in shares of Moderna by 79.8% during the fourth quarter. Amundi now owns 1,206,273 shares of the company's stock valued at $52,075,000 after acquiring an additional 535,273 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Moderna by 39.1% during the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares in the last quarter. AMF Tjanstepension AB purchased a new stake in Moderna in the fourth quarter worth $1,464,000. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new stake in Moderna in the fourth quarter valued at $220,000. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.29 during midday trading on Friday, hitting $34.59. 5,867,717 shares of the company's stock traded hands, compared to its average volume of 12,353,019. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock has a market capitalization of $13.34 billion, a price-to-earnings ratio of -3.73 and a beta of 1.86. The firm has a fifty day moving average of $36.09 and a 200 day moving average of $47.92.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have commented on MRNA shares. Piper Sandler restated an "overweight" rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a report on Monday, November 18th. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Wednesday, January 15th. Argus lowered Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. set a $45.00 price target on Moderna in a research report on Friday, February 14th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $59.60.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.